103 related articles for article (PubMed ID: 30904743)
1. Treatment of type 2 diabetes mellitus worldwide: Baseline patient characteristics in the global DISCOVER study.
Gomes MB; Rathmann W; Charbonnel B; Khunti K; Kosiborod M; Nicolucci A; Pocock SJ; Shestakova MV; Shimomura I; Tang F; Watada H; Chen H; Cid-Ruzafa J; Fenici P; Hammar N; Surmont F; Ji L;
Diabetes Res Clin Pract; 2019 May; 151():20-32. PubMed ID: 30904743
[TBL] [Abstract][Full Text] [Related]
2. Treatment patterns and associated factors in 14 668 people with type 2 diabetes initiating a second-line therapy: Results from the global DISCOVER study programme.
Nicolucci A; Charbonnel B; Gomes MB; Khunti K; Kosiborod M; Shestakova MV; Shimomura I; Watada H; Chen H; Cid-Ruzafa J; Fenici P; Hammar N; Surmont F; Tang F; Pocock S
Diabetes Obes Metab; 2019 Nov; 21(11):2474-2485. PubMed ID: 31297947
[TBL] [Abstract][Full Text] [Related]
3. Glycaemic control in patients with type 2 diabetes initiating second-line therapy: Results from the global DISCOVER study programme.
Khunti K; Chen H; Cid-Ruzafa J; Fenici P; Gomes MB; Hammar N; Ji L; Kosiborod M; Pocock S; Shestakova MV; Shimomura I; Tang F; Watada H; Nicolucci A;
Diabetes Obes Metab; 2020 Jan; 22(1):66-78. PubMed ID: 31468637
[TBL] [Abstract][Full Text] [Related]
4. Characteristics and Treatment Patterns of Patients with Type 2 Diabetes Mellitus in the Middle East and Africa Cohort of the DISCOVER Study Program: a Prospective Study.
Al-Rubeaan K; Alsayed M; Ben-Nakhi A; Bayram F; Echtay A; Hadaoui A; Hafidh K; Kennedy K; Kok A; Malek R; Rajadhyaksha V; Arnold SV
Diabetes Ther; 2022 Jul; 13(7):1339-1352. PubMed ID: 35689732
[TBL] [Abstract][Full Text] [Related]
5. Metformin discontinuation in patients beginning second-line glucose-lowering therapy: results from the global observational DISCOVER study programme.
Khunti K; Gomes MB; Kosiborod M; Nicolucci A; Pocock S; Rathmann W; Shestakova MV; Shimomura I; Watada H; Chen H; Cid-Ruzafa J; Fenici P; Hammar N; Tang F; Ji L;
BMJ Open; 2020 Aug; 10(8):e034613. PubMed ID: 32868349
[TBL] [Abstract][Full Text] [Related]
6. Vascular complications in patients with type 2 diabetes: prevalence and associated factors in 38 countries (the DISCOVER study program).
Kosiborod M; Gomes MB; Nicolucci A; Pocock S; Rathmann W; Shestakova MV; Watada H; Shimomura I; Chen H; Cid-Ruzafa J; Fenici P; Hammar N; Surmont F; Tang F; Khunti K;
Cardiovasc Diabetol; 2018 Nov; 17(1):150. PubMed ID: 30486889
[TBL] [Abstract][Full Text] [Related]
7. Early glycaemic control in metformin users receiving their first add-on therapy: a population-based study of 4,734 people with type 2 diabetes.
Thomsen RW; Baggesen LM; Søgaard M; Pedersen L; Nørrelund H; Buhl ES; Haase CL; Johnsen SP
Diabetologia; 2015 Oct; 58(10):2247-53. PubMed ID: 26277380
[TBL] [Abstract][Full Text] [Related]
8. Important differences in the durability of glycaemic response among second-line treatment options when added to metformin in type 2 diabetes: a retrospective cohort study.
Mamza J; Mehta R; Donnelly R; Idris I
Ann Med; 2016; 48(4):224-34. PubMed ID: 26982210
[TBL] [Abstract][Full Text] [Related]
9. Treatment patterns and glycated haemoglobin levels over 36 months in individuals with type 2 diabetes initiating second-line glucose-lowering therapy: The global DISCOVER study.
Charbonnel BH; Chen H; Cid-Ruzafa J; Cooper A; Fenici P; Gomes MB; Saraiva GL; Medina J; Nicolucci A; Shestakova MV; Shimomura I; Surmont F; Tang F; Vora J; Watada H; Khunti K;
Diabetes Obes Metab; 2023 Jan; 25(1):46-55. PubMed ID: 36111434
[TBL] [Abstract][Full Text] [Related]
10. A UK nationwide prospective study of treatment change in MODY: genetic subtype and clinical characteristics predict optimal glycaemic control after discontinuing insulin and metformin.
Shepherd MH; Shields BM; Hudson M; Pearson ER; Hyde C; Ellard S; Hattersley AT; Patel KA;
Diabetologia; 2018 Dec; 61(12):2520-2527. PubMed ID: 30229274
[TBL] [Abstract][Full Text] [Related]
11. Type 2 Diabetes Mellitus Treatment Patterns Across Europe: A Population-based Multi-database Study.
Overbeek JA; Heintjes EM; Prieto-Alhambra D; Blin P; Lassalle R; Hall GC; Lapi F; Bianchini E; Hammar N; Bezemer ID; Herings RMC
Clin Ther; 2017 Apr; 39(4):759-770. PubMed ID: 28342563
[TBL] [Abstract][Full Text] [Related]
12. Type 2 diabetes treatment and outcomes worldwide: A short review of the DISCOVER study programme.
Khunti K; Ji L; Medina J; Surmont F; Kosiborod M
Diabetes Obes Metab; 2019 Nov; 21(11):2349-2353. PubMed ID: 31215715
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular safety of glucose-lowering agents as add-on medication to metformin treatment in type 2 diabetes: report from the Swedish National Diabetes Register.
Ekström N; Svensson AM; Miftaraj M; Franzén S; Zethelius B; Eliasson B; Gudbjörnsdottir S
Diabetes Obes Metab; 2016 Oct; 18(10):990-8. PubMed ID: 27282621
[TBL] [Abstract][Full Text] [Related]
14. Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled phase III trial with a 34-week active-controlled extension.
Barnett AH; Patel S; Harper R; Toorawa R; Thiemann S; von Eynatten M; Woerle HJ
Diabetes Obes Metab; 2012 Dec; 14(12):1145-54. PubMed ID: 22974280
[TBL] [Abstract][Full Text] [Related]
15. Impact of insulin sensitivity, beta-cell function and glycaemic control on initiation of second-line glucose-lowering treatment in newly diagnosed type 2 diabetes.
Rathmann W; Strassburger K; Bongaerts B; Bobrov P; Kuss O; Müssig K; Markgraf DF; Szendroedi J; Herder C; Roden M;
Diabetes Obes Metab; 2017 Jun; 19(6):866-873. PubMed ID: 28127851
[TBL] [Abstract][Full Text] [Related]
16. Baseline Characteristics of Patients with Type 2 Diabetes Initiating Second-Line Treatment in Japan: Findings from the J-DISCOVER Study.
Katakami N; Mita T; Takahara M; Yajima T; Wada F; Kawashima M; Shimomura I; Watada H;
Diabetes Ther; 2020 Jul; 11(7):1563-1578. PubMed ID: 32504219
[TBL] [Abstract][Full Text] [Related]
17. Prevalence and risk factors of vascular complications in type 2 diabetes mellitus: Results from discover Middle East and Africa cohort.
Hafidh K; Malek R; Al-Rubeaan K; Kok A; Bayram F; Echtay A; Rajadhyaksha V; Hadaoui A
Front Endocrinol (Lausanne); 2022; 13():940309. PubMed ID: 36017310
[TBL] [Abstract][Full Text] [Related]
18. Baseline characteristic differences between patients prescribed sitagliptin vs. other oral antihyperglycemic agents: analysis of a US electronic medical record database.
Zhang Q; Rajagopalan S; Mavros P; Engel SS; Davies MJ; Yin D; Radican L
Curr Med Res Opin; 2010 Jul; 26(7):1697-703. PubMed ID: 20465367
[TBL] [Abstract][Full Text] [Related]
19. What next after metformin? A retrospective evaluation of the outcome of second-line, glucose-lowering therapies in people with type 2 diabetes.
Morgan CL; Poole CD; Evans M; Barnett AH; Jenkins-Jones S; Currie CJ
J Clin Endocrinol Metab; 2012 Dec; 97(12):4605-12. PubMed ID: 23076348
[TBL] [Abstract][Full Text] [Related]
20. Long-term Trends in Antidiabetes Drug Usage in the U.S.: Real-world Evidence in Patients Newly Diagnosed With Type 2 Diabetes.
Montvida O; Shaw J; Atherton JJ; Stringer F; Paul SK
Diabetes Care; 2018 Jan; 41(1):69-78. PubMed ID: 29109299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
